AirSculpt Technologies, Inc. (NASDAQ:AIRS) CEO Dennis Dean Sells 7,719 Shares

AirSculpt Technologies, Inc. (NASDAQ:AIRS) CEO Dennis Dean sold 7,719 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.53, for a total value of $58,124.07. Following the completion of the sale, the chief executive officer now owns 628,940 shares in the company, valued at approximately $4,735,918.20. This represents a 1.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Dennis Dean also recently made the following trade(s):

• On Friday, November 15th, Dennis Dean sold 24,510 shares of AirSculpt Technologies stock. The shares were sold at an average price of $6.54, for a total transaction of $160,295.40.

AirSculpt Technologies Price Performance

AIRS opened at $6.51 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.86 and a current ratio of 0.51. The company has a market capitalization of $376.81 million, a P/E ratio of -46.50 and a beta of 1.57. AirSculpt Technologies, Inc. has a 1-year low of $2.92 and a 1-year high of $9.20. The company has a 50-day moving average of $5.55 and a 200-day moving average of $4.75.

AirSculpt Technologies (NASDAQ:AIRS) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). The business had revenue of $42.55 million for the quarter, compared to analyst estimates of $42.49 million. AirSculpt Technologies had a positive return on equity of 2.22% and a negative net margin of 4.13%. During the same quarter in the prior year, the firm posted ($0.01) earnings per share. Equities analysts expect that AirSculpt Technologies, Inc. will post 0.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, BTIG Research started coverage on AirSculpt Technologies in a report on Thursday, October 17th. They issued a “neutral” rating for the company. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.50.

Institutional Investors Weigh In On AirSculpt Technologies

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in shares of AirSculpt Technologies by 6.4% during the 3rd quarter. Geode Capital Management LLC now owns 355,540 shares of the company’s stock valued at $1,803,000 after acquiring an additional 21,339 shares in the last quarter. Barclays PLC raised its stake in shares of AirSculpt Technologies by 227.0% in the 3rd quarter. Barclays PLC now owns 19,100 shares of the company’s stock valued at $97,000 after buying an additional 13,259 shares in the last quarter. SW Investment Management LLC grew its stake in shares of AirSculpt Technologies by 5.0% in the 2nd quarter. SW Investment Management LLC now owns 4,500,000 shares of the company’s stock valued at $18,000,000 after purchasing an additional 213,677 shares during the period. FourWorld Capital Management LLC acquired a new stake in shares of AirSculpt Technologies during the first quarter worth approximately $557,000. Finally, Vanguard Group Inc. grew its holdings in AirSculpt Technologies by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 576,038 shares of the company’s stock worth $3,537,000 after acquiring an additional 5,606 shares during the last quarter. 91.54% of the stock is owned by hedge funds and other institutional investors.

About AirSculpt Technologies

AirSculpt Technologies, Inc, together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure.